Petrovax is ready to participate in auctions after the price of Prevenar 13 vaccine is reviewed


Russian biopharmaceutical company Petrovax is ready to participate in auctions for public procurement of Pfizer’s Prevenar 13 pneumococcal vaccine after a new price for the drug is registered. This was reported in the press service of Petrovax.

“The documents for the revision of the VED-listed price for Prevenar 13 vaccine have been submitted, and the application review process is underway. The VED-listed price for the vaccine has not been indexed since 2014. Since then, significant inflation has accumulated, which we ask to partially compensate within the framework of the existing procedures. We are ready to participate in auctions that will be announced after the price is re–registered,” TASS quotes the company’s statement.

Earlier, the Kommersant newspaper, with reference to the FAS of the Russian Federation, reported that the agency had received an application for a review of the price of Preventar. According to the newspaper, the manufacturers – Sanofi, Pfizer and their Russian partners – refused to participate in auctions, since the supply of the drugs is unprofitable even at the maximum purchase price due to currency fluctuations and the significant growth of logistics costs.

As Petrovax noted, in the current transition period, the company has delivered the vaccine to the regions of the Russian Federation, including under state contracts that cover the demand for it for several months. Petrovax implements full-cycle production of Prevenar 13 vaccine as a finished dosage form in cooperation with Pfizer.

Petrovax earlier announced its import substitution plans in respect of an orphan disease therapy.